PL346011A1 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
PL346011A1
PL346011A1 PL99346011A PL34601199A PL346011A1 PL 346011 A1 PL346011 A1 PL 346011A1 PL 99346011 A PL99346011 A PL 99346011A PL 34601199 A PL34601199 A PL 34601199A PL 346011 A1 PL346011 A1 PL 346011A1
Authority
PL
Poland
Prior art keywords
coadministration
acat
treatment
atherosclerotic lesions
mmp inhibitors
Prior art date
Application number
PL99346011A
Other languages
English (en)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PL346011A1 publication Critical patent/PL346011A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
PL99346011A 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions PL346011A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
PL346011A1 true PL346011A1 (en) 2002-01-14

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99346011A PL346011A1 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (id)
JP (1) JP2002521328A (id)
KR (1) KR20010083134A (id)
CN (1) CN1310629A (id)
AP (1) AP2001002035A0 (id)
AU (1) AU4701799A (id)
BG (1) BG105162A (id)
BR (1) BR9912296A (id)
CA (1) CA2335062A1 (id)
CZ (1) CZ2001126A3 (id)
EA (1) EA200100153A1 (id)
EE (1) EE200100046A (id)
HR (1) HRP20010055A2 (id)
HU (1) HUP0102880A3 (id)
ID (1) ID30030A (id)
IL (1) IL140982A0 (id)
IS (1) IS5809A (id)
NO (1) NO20010291L (id)
OA (1) OA11584A (id)
PL (1) PL346011A1 (id)
SK (1) SK502001A3 (id)
TR (1) TR200100205T2 (id)
WO (1) WO2000004892A2 (id)
YU (1) YU3501A (id)
ZA (1) ZA200100294B (id)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1210401A (en) * 1999-11-05 2001-06-06 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
WO2002020009A1 (fr) * 2000-09-01 2002-03-14 Sankyo Company, Limited Compositions medicales
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
JP4617449B2 (ja) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
GEP20012511B (en) * 1995-08-04 2001-08-27 Warner Lambert Co Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
EA001561B1 (ru) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
NZ333063A (en) * 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ID30030A (id) 2001-11-01
AU4701799A (en) 2000-02-14
IS5809A (is) 2001-01-12
HUP0102880A3 (en) 2002-11-28
CZ2001126A3 (cs) 2002-01-16
TR200100205T2 (tr) 2001-05-21
NO20010291D0 (no) 2001-01-18
HRP20010055A2 (en) 2002-04-30
WO2000004892A2 (en) 2000-02-03
CN1310629A (zh) 2001-08-29
YU3501A (sh) 2005-06-10
ZA200100294B (en) 2002-01-10
AP2001002035A0 (en) 2001-03-31
NO20010291L (no) 2001-01-18
KR20010083134A (ko) 2001-08-31
CA2335062A1 (en) 2000-02-03
OA11584A (en) 2004-07-20
EP1098662A2 (en) 2001-05-16
EA200100153A1 (ru) 2001-08-27
BG105162A (en) 2001-12-29
HUP0102880A2 (en) 2002-06-29
EE200100046A (et) 2002-06-17
SK502001A3 (en) 2002-06-04
BR9912296A (pt) 2001-04-17
IL140982A0 (en) 2002-02-10
JP2002521328A (ja) 2002-07-16
WO2000004892A3 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
GB9800795D0 (en) Prevention of multiple use of limited use devices
EP1100392A4 (en) METHODS AND DEVICES FOR REDUCING THE MINERAL CONTENT OF VASCULAR CALCIFIED LESIONS
HUP0101613A3 (en) Metalloprotease inhibitor (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides and medicaments containing the same
AU2212299A (en) Compositions and methods for the treatment of tumor
HK1094909A1 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis il-18
HU0900792D0 (en) Use of renin-angiotensin inhibitors
PL341335A1 (en) Combination of ace and mmp inhibitors
HU9802971D0 (en) The use of mmp inhibitors for the treatments of ocular angiogenesis
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
GB2342045B (en) Mineral and vitamin combinations for the treatment of stress and allergies
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
PL346011A1 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
HK1041827B (zh) 用於治療雌激素依賴性疾病的化合物以及製備和使用上述化合物的方法
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
EP0983958A4 (en) STAIRCASE AND STAIRCASE STEP
HUP0101947A3 (en) Combination for the treatment of tumors
NO20004920D0 (no) Anvendelse av proteaseinhibitorer for behandling av hudskader
IL142471A0 (en) Fluticasone lotion having improved vasoconstrictor activity
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
IL141056A0 (en) Protease inhibitors for use in the treatment of psoriasis
AU1940800A (en) Combination therapy for the treatment of sepsis
AU1292000A (en) Device and method for the direct reduction of iron oxides
EP1135141A4 (en) PHOSPHOLIPASE INHIBITORS FOR TREATING CANCER
EP1086261A4 (en) ANTI-CORROSION TREATMENT
GB2343629B (en) Treatment of cellulite